Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.
Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å. Haakensen VD, et al. Among authors: farooqi s. Eur J Cancer. 2024 May;202:113973. doi: 10.1016/j.ejca.2024.113973. Epub 2024 Mar 1. Eur J Cancer. 2024. PMID: 38447379 Free article. Clinical Trial.
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å. Haakensen VD, et al. J Transl Med. 2021 May 31;19(1):232. doi: 10.1186/s12967-021-02905-3. J Transl Med. 2021. PMID: 34059094 Free PMC article. Clinical Trial.
[Immunotherapy for malignant pleural mesothelioma].
Farooqi SJ, Bjaanæs MM, Helland Å, Haakensen VD. Farooqi SJ, et al. Tidsskr Nor Laegeforen. 2021 Sep 6;141. doi: 10.4045/tidsskr.21.0503. Print 2021 Sep 7. Tidsskr Nor Laegeforen. 2021. PMID: 34505475 Free article. Norwegian. No abstract available.
IMPROVE 2022 International Meeting on Pathway-Related Obesity: Vision of Excellence.
Kühnen P, Argente J, Clément K, Dollfus H, Dubern B, Farooqi S, de Groot C, Grüters A, Holm JC, Hopkins M, Kleinendorst L, Körner A, Meeker D, Rydén M, von Schnurbein J, Tschöp M, Yeo GSH, Zorn S, Wabitsch M. Kühnen P, et al. Among authors: farooqi s. Clin Obes. 2024 Apr 11:e12659. doi: 10.1111/cob.12659. Online ahead of print. Clin Obes. 2024. PMID: 38602039
Obesity and thinness: insights from genetics.
Farooqi S. Farooqi S. Philos Trans R Soc Lond B Biol Sci. 2023 Oct 23;378(1888):20220205. doi: 10.1098/rstb.2022.0205. Epub 2023 Sep 4. Philos Trans R Soc Lond B Biol Sci. 2023. PMID: 37661743 Free PMC article. Review.
Halloysite nanotubes-cellulose ether based biocomposite matrix, a potential sustained release system for BCS class I drug verapamil hydrochloride: Compression characterization, in-vitro release kinetics, and in-vivo mechanistic physiologically based pharmacokinetic modeling studies.
Husain T, Shoaib MH, Ahmed FR, Yousuf RI, Siddiqui F, Saleem MT, Farooqi S, Jabeen S. Husain T, et al. Among authors: farooqi s. Int J Biol Macromol. 2023 Aug 19;251:126409. doi: 10.1016/j.ijbiomac.2023.126409. Online ahead of print. Int J Biol Macromol. 2023. PMID: 37598820
High risk and low prevalence diseases: Thyroid storm.
Farooqi S, Raj S, Koyfman A, Long B. Farooqi S, et al. Am J Emerg Med. 2023 Jul;69:127-135. doi: 10.1016/j.ajem.2023.03.035. Epub 2023 Mar 27. Am J Emerg Med. 2023. PMID: 37104908 Review.
124 results